%0 Journal Article
%A Livingstone, E.
%A Gogas, H.
%A Kandolf-Sekulovic, L.
%A Meier, F.
%A Eigentler, T. K.
%A Ziemer, M.
%A Terheyden, P. A. M.
%A Gesierich, A. H.
%A Herbst, R. A.
%A Kähler, K. C.
%A Ziogas, D. C.
%A Mijuskovic, Z.
%A Garzarolli, M.
%A Garbe, C.
%A Roesch, A.
%A Ugurel, S.
%A Gutzmer, R.
%A Grob, J. J.
%A Kiecker, F.
%A Utikal, J.
%A Windemuth-Kieselbach, C.
%A Eckhardt, S.
%A Zimmer, L.
%A Schadendorf, D.
%T Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial.
%J European journal of cancer
%V 190
%@ 0014-2964
%C Amsterdam [u.a.]
%I Elsevier
%M DKFZ-2023-01425
%P 112941
%D 2023
%X ImmunoCobiVem investigated whether a planned switch to atezolizumab after achieving tumour control during run-in with vemurafenib + cobimetinib improves progression-free survival (PFS) and overall survival (OS) compared to continuous targeted therapy (TT) in patients with previously untreated advanced BRAFV600-mutated melanoma.In this multicenter phase 2 study, patients received vemurafenib plus cobimetinib. After 3months, patients without progressive disease (PD) were randomly assigned (1:1) to continue vemurafenib + cobimetinib (Arm A) or switch to atezolizumab (Arm B) until first documented PD (PD1). Primary outcome was PFS1 (time from start of run-in until PD1 or death). OS and safety were also assessed.Of 185 patients enroled between November 2016 and December 2019, 135 were randomly assigned after the run-in period (Arm A, n = 69; Arm B, n = 66). Median PFS1 was significantly longer in Arm A versus Arm B (13.9 versus 5.9months; hazard ratio [HR] 0.55; 95
%K Checkpoint inhibition (Other)
%K First-line (Other)
%K Melanoma (Other)
%K Run-in (Other)
%K Sequence (Other)
%K Targeted therapy (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37482012
%R 10.1016/j.ejca.2023.112941
%U https://inrepo02.dkfz.de/record/277708